CirrhoCare in COVID-19: A Pilot, Remote, Home Monitoring Study in Advanced Cirrhosis
NCT05045924 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2021-09-16
Summary
The COVID-19 outbreak has exposed many strengths and weaknesses of delivering healthcare, and we want to assess whether patients with advanced liver cirrhosis can be effectively monitored at home, to limit hospital visits and thereby their infection risks. We also wish to show that if they have new signs of clinical deterioration, that these can be picked up quickly even in the community, and can result in early review or appropriate treatment. This study has been funded by INNOVATE UK, who are seeking novel ways and technologies to improve health during the pressures of the COVID pandemic.
Taking part in this study involves a consultation with the investigating doctor and being shown how to use a phone-based App and the supplied CirrhoCare equipment (Withings Watch, scales, and Blood Pressure cuff). Patients will be shown how to use the equipment for several simple daily assessments, including:
Heart rate (ECG) readings via the supplied Withings Watch. This would take approximately 7-10 minutes to perform each day.
Daily weight, using a special weighing scale that also measures the amount of body water and muscle percentages (takes 30 seconds to perform).
Digital blood pressure measurement, using the supplied cuff. This would take approximately 2 minutes to perform daily.
For all the above measurements, that are entirely automated, the patient will be guided via the mobile phone App with step-by-step video instructions. In addition, they will be given printed instructions. Individuals will be asked to perform the measurements through daily prompts built into the App, and be sent reminders, in case they forget. If they have difficulties with any of the tasks, there is also an App based support system, where they can send a message for the trial team to provide assistance.
In addition to the measurements above, patients will be prompted to click on a memory testing exercise of naming animals (termed - 'Stroop test'), which will be performed after the daily morning measurements. This can take half a minute to up to four minutes to perform, depending on an individual's memory function.
The equipment will be supplied will enable daily monitoring for a maximum of 3 months in this study. We will also be able to learn from the supplied watch, how much sleep and how much daily exercise patients get, which will help us assess general physical well-being. Furthermore, patients will be aksed to supply information on the amount of fluid and food they have consumed via simple 'click' functions on the App (e.g. clicking next to the picture denoting 4 glasses of water). Patients will be prompted to do this via smartphone and watch every evening.
We will seek patient feedback on using the App through a brief in-App based questionnaire, after 4, 8 and 12 weeks of study. In addition, patients will fill in a quality of life questionnaire before they start using the equipment, and then again after 4 weeks and 12 weeks. These brief questionnaires are through simple drop-down menus on the App and take less than 5 minutes to complete.
At the end of 12 weeks, or if individuals leave the study earlier, all the equipment will be returned to the investigating team, to analyse the data.
In addition to the data that we will collect from the digital tools described above, we will also access routine blood tests performed when determined necessary by the liver doctors, as part of the standard of care.
Conditions
- Decompensated Cirrhosis
Sponsors & Collaborators
-
Innovate UK
collaborator OTHER_GOV -
Royal Free Hospital NHS Foundation Trust
lead OTHER
Principal Investigators
-
Rajeshwar Mookerjee, MBBS, PhD · Royal Free Hospital NHS Foundation Trust
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-01
- Primary Completion
- 2021-11-30
- Completion
- 2021-11-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
NCT06855056 ·Status: RECRUITING
-
Health IT Generated PROs to Improve Outcomes in Cirrhosis
NCT03564626 ·Status: COMPLETED ·Phase: NA
-
Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis
NCT05033327 ·Status: COMPLETED ·Phase: NA
-
The Cirrhosis Outpatient Optimization, Readmission & Safety Study
NCT02457988 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Hospital @ Home Model of Care for Cirrhosis
NCT06396897 ·Status: RECRUITING ·Phase: NA
-
Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis
NCT02534805 ·Status: COMPLETED
-
The Impact of Liver Cirrhosis on Outcomes in Trauma Patients
NCT05170854 ·Status: ACTIVE_NOT_RECRUITING
-
Telehealth Intervention in Cirrhotics
NCT03969186 ·Status: COMPLETED ·Phase: NA
-
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
NCT06263816 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Surrogate Markers of Portal Pressure
NCT02508298 ·Status: COMPLETED ·Phase: NA
-
Flicker App for Minimal Hepatic Encephalopathy
NCT04415294 ·Status: UNKNOWN
-
Short Term Outcomes in Hospitalized Patients With Liver Cirrhosis
NCT05848414 ·Status: COMPLETED
-
Evaluation of the Role of Plasma Biomarkers in the Development of Decompensation in Patients With Cirrhosis .
NCT03084185 ·Status: UNKNOWN
-
Infections in Hospitalized Cirrhotic Patients
NCT03137719 ·Status: COMPLETED
-
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
NCT04422223 ·Status: UNKNOWN
-
Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
NCT05413083 ·Status: ACTIVE_NOT_RECRUITING
-
Hemodynamic Alterations in Liver Cirrhosis Validated by Non-invasive MR Compared to Invasive Assessment
NCT03443934 ·Status: COMPLETED
-
MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis
NCT03438916 ·Status: COMPLETED
-
Indocyangreen Elimination in Cirrhosis and Acute Liver Failure
NCT00245310 ·Status: COMPLETED
-
AlcoChange: An Open Label Pilot Study of Smartphone Monitoring for Alcoholic Liver Disease
NCT03474328 ·Status: UNKNOWN ·Phase: NA
-
Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal
NCT01059396 ·Status: COMPLETED ·Phase: PHASE4
-
Predictive Utility of DASIMAR as a Prognostic Biomarker in Acute-on-chronic Liver Failure (ACLF)
NCT01071746 ·Status: UNKNOWN
-
Acute-On-Chronic Liver Failure In Cirrhotic Patients
NCT04790435 ·Status: COMPLETED
-
Longitudinal Monitoring of Inflammation in Cirrhosis
NCT05538962 ·Status: COMPLETED ·Phase: NA
-
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
NCT07087041 ·Status: NOT_YET_RECRUITING